204 hasil
Menampilkan 1–20 · 0,14 detik · RSS
Kidney Cancer
Scopus
ISSN 2468-4562 · SAGE Publishing · 204 artikel di indeks
-
Artikel Jurnal
Pathology of Pediatric Renal Tumors
Renal tumors in the pediatric age group are a unique group of tumors that are generally quite distinct from tumors arising in the adult kidney. This review covers benign and malignant renal tumors commonly presenting in the pediatric population. Pertinent clinical, epidemiologic, macroscopic, and…
-
Artikel Jurnal
Diagnosis of Papillary Renal Cell Carcinoma – the Current Perspective
Papillary renal cell carcinoma (pRCC) represents the second most common renal cell carcinoma. Diagnosis of pRCC has been challenged by emergence of several novel renal tumor entities with papillary morphology. Some of these have been found to constitute independent entities with specific molecular…
-
Artikel Jurnal
Renal Medullary Carcinoma: A Contemporary Update
SMARCB1-deficient renal medullary carcinoma is one of the most aggressive forms of kidney cancer and mainly affects individuals with sickle hemoglobinopathies. Herein, we have sought to provide a contemporary update regarding our understanding of this entity. Recent studies have improved our…
-
Artikel Jurnal
Staging, Grading, and Emerging Prognostic Factors in Renal Cell Carcinoma
Renal cell carcinoma (RCC) makes up most adult kidney cancers. The classic presentation is a spherical, well-circumscribed mass, but fewer subtypes present as more infiltrative neoplasms. Both growth patterns can affect tumor staging and prognosis. Accordingly, this review will discuss the current…
-
Artikel Jurnal
Mesenchymal Tumors of the Kidney in Adults
Mesenchymal neoplasms of the kidney encompass a wide range of tumor types with heterogeneous clinical, histologic, and molecular features. Given their rarity relative to renal epithelial neoplasms, diagnosis may be challenging. In this review, the clinicopathologic and molecular characteristics of…
-
Artikel Jurnal
External validation of automated CT volumetry in renal tumor volume measurement and its surgical implications
Background Accurate renal tumor anatomy description is crucial for improving surgical and oncological outcomes. CT advancements assist in surgical planning by determining renal tumor volume. Objectives To examine the accuracy and precision of CT in renal tumor volume measurement and to assess the…
-
Artikel Jurnal
Renal Tumors Associated with Chronic Kidney Disease
The incidence and prevalence of chronic kidney disease (CKD) and end stage renal disease (ESRD) are on the rise causing significant health issues associated with hemodialysis, peritoneal dialysis and kidney transplantation. Moreover, all CKD patients have dramatically higher risk than the general…
-
Artikel Jurnal
Differential Diagnosis of Renal Neoplasia with Defined Molecular Alterations
Renal cell carcinoma (RCC) is linked to signature molecular alterations that influence their morphological characteristics and associated clinicopathologic features. This has been fueled by an incremental understanding of the molecular underpinnings of RCC. The current 2022 WHO classification has…
-
Artikel Jurnal
Unveiling the Spectrum: Insights into Benign Renal Neoplasms
Renal tumors (i.e., abnormal growths within the kidney) encompass both benign and malignant entities. The pathologist plays a key role in determining the nature of the growth (i.e., benign or malignant) by evaluating the tumor with a microscope. It is essential to distinguish between these two…
-
Artikel Jurnal
Renal Tumors Associated with Familial Syndromes – Updates on Diagnosis and Clinical Implication
Renal tumors associated with familial syndromes, characterized by germline mutations in specific genes such as VHL , MET , FLCN , TSC1 , TSC2 , FH , and SDHB , offer critical insights into renal cell carcinoma tumorigenesis and necessitate tailored genetic counseling, screening, and surveillance…
-
Artikel Jurnal
Durable responses to immune checkpoint inhibitor-based regimens for metastatic clear cell renal cell carcinoma stratified by IMDC risk groups: A pooled analysis of four randomized phase 3 trials
Background An immune checkpoint inhibitor (ICI) backbone is a standard of care for frontline metastatic clear cell renal cell carcinoma, involving either ICI doublet or tyrosine kinase inhibitor (TKI) with ICI. These phase 3 trials used a sunitinib control arm. The optimal regimen is uncertain…
-
Artikel Jurnal
Differential Diagnosis of Renal Neoplasia with Clear Cell Cytology
Tumors with clear cells represent the most common group of renal neoplasms, with clear cell renal cell carcinoma (RCC) remaining the prototypical entity. Consequently, it is important to distinguish clear cell RCC from other entities with clear cell morphology, including TFE3-rearranged RCC…
-
Artikel Jurnal
Role of immune check point inhibitor rechallenge in metastatic renal cell carcinoma
Immune checkpoint inhibitors (ICIs) have revolutionized treatment of metastatic renal cell carcinoma (mRCC), yet the role and efficacy of ICI rechallenge after disease progression remain uncertain. Response-adaptive escalation in OMNIVORE, HCRN GU16-260, and TITAN-RCC trials showed limited…
-
Artikel Jurnal
Assessing genetic and urologic providers on renal screening recommendations for individuals with a familial renal cancer risk
Background: While hereditary renal cell carcinoma (RCC) syndromes account for up to 16% of RCC cases and have screening guidelines; no screening recommendations exist for individuals with family history of RCC and negative genetic testing (familial RCC risk). Objective: This study aimed to assess…
-
Artikel Jurnal
Spatial clustering of immunosuppressive macrophages in papillary renal cell carcinoma
Background Papillary renal cell carcinoma (pRCC) is the second most common kidney cancer subtype, yet our understanding of its tumor immune microenvironment (TIME) remains limited. Objective We utilized multiplex immunofluorescence (mIF) and spatial transcriptomics (ST) to evaluate immune cell…
-
Artikel Jurnal
Pragmatic trials in renal cell carcinoma
Therapeutic options for Renal Cell Carcinoma (RCC) are rapidly advancing. Systemic immune-oncology (IO) treatments, including immune checkpoint inhibitor (ICI) combination therapy and ICI with vascular endothelial growth factor tyrosine kinase inhibitors (VEGF TKIs), have shown substantial overall…
-
Artikel Jurnal
Renal biopsy in the era of immune-based combination therapies for metastatic renal cell carcinoma: Current practices and considerations
The rise of immune-based combination therapies has revolutionized the treatment landscape for metastatic renal cell carcinoma (mRCC), offering significant improvements in response rates and survival. However, along with these advancements come challenges in managing treatment-related adverse…